BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21779816)

  • 1. Is there an additional benefit of serial NT-proBNP measurements in patients with stable chronic heart failure receiving individually optimized therapy?
    Franke J; Frankenstein L; Schellberg D; Bajrovic A; Wolter JS; Ehlermann P; Doesch AO; Nelles M; Katus HA; Zugck C
    Clin Res Cardiol; 2011 Dec; 100(12):1059-67. PubMed ID: 21779816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbohydrate antigen-125 and N-terminal pro-brain natriuretic peptide levels: compared in heart-failure prognostication.
    Ordu S; Ozhan H; Alemdar R; Aydin M; Caglar O; Yuksel H; Kandis H
    Tex Heart Inst J; 2012; 39(1):30-5. PubMed ID: 22412224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure.
    Zhang J; Pellicori P; Pan D; Dierckx R; Clark AL; Cleland JGF
    Int J Cardiol; 2018 Oct; 269():196-200. PubMed ID: 30001941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent Heart Failure and Death in Patients with Stable Coronary Artery Disease: The Heart and Soul Study.
    Mishra RK; Judson G; Christenson RH; DeFilippi C; Wu AHB; Whooley MA
    Cardiology; 2017; 137(4):201-206. PubMed ID: 28445886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study.
    Eurlings LW; Sanders-van Wijk S; van Kraaij DJ; van Kimmenade R; Meeder JG; Kamp O; van Dieijen-Visser MP; Tijssen JG; Brunner-La Rocca HP; Pinto YM
    J Card Fail; 2014 Dec; 20(12):881-90. PubMed ID: 25175696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure.
    Carubelli V; Lombardi C; Lazzarini V; Bonadei I; Castrini AI; Gorga E; Richards AM; Metra M
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):828-39. PubMed ID: 27322401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The minimal informative monitoring interval of N-terminal pro-B-type natriuretic peptide in patients with stable heart failure.
    Dai Z; Asano T; Takahashi O; Komiyama N; Ohde S
    BMC Cardiovasc Disord; 2020 Jun; 20(1):262. PubMed ID: 32487160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels.
    Carrasco-Sánchez FJ; Pérez-Calvo JI; Morales-Rull JL; Galisteo-Almeda L; Páez-Rubio I; Barón-Franco B; Aguayo-Canela M; Pujol-De la llave E
    J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):115-21. PubMed ID: 24522084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement.
    Stähli BE; Gebhard C; Saleh L; Falk V; Landmesser U; Nietlispach F; Maisano F; Lüscher TF; Maier W; Binder RK
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1240-7. PubMed ID: 25511571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure.
    Noveanu M; Breidthardt T; Potocki M; Reichlin T; Twerenbold R; Uthoff H; Socrates T; Arenja N; Reiter M; Meissner J; Heinisch C; Stalder S; Mueller C
    Crit Care; 2011; 15(1):R1. PubMed ID: 21208408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events.
    Tziakas DN; Chalikias GK; Stakos D; Chatzikyriakou SV; Papazoglou D; Mitrousi K; Lantzouraki A; Thomaidi A; Boudoulas H; Konstantinides S
    Eur J Prev Cardiol; 2012 Feb; 19(1):62-71. PubMed ID: 20479644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single sST2 protein measurement predicts adverse outcomes at 1-year follow-up in patients with chronic heart failure.
    Sobczak S; Wojtczak-Soska K; Ciurus T; Sakowicz A; Pietrucha T; Lelonek M
    Pol Arch Med Wewn; 2014; 124(9):452-8. PubMed ID: 25041760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender : Results from the PROBE-HF study.
    Ballo P; Betti I; Barchielli A; Balzi D; Castelli G; De Luca L; Gheorghiade M; Zuppiroli A
    Clin Res Cardiol; 2016 May; 105(5):421-31. PubMed ID: 26547915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure.
    Gardner RS; Chong KS; Morton JJ; McDonagh TA
    J Card Fail; 2005 Jun; 11(5 Suppl):S47-53. PubMed ID: 15948101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic utility of the Seattle Heart Failure Score and amino terminal pro B-type natriuretic peptide in varying stages of systolic heart failure.
    Adlbrecht C; Hülsmann M; Neuhold S; Strunk G; Pacher R
    J Heart Lung Transplant; 2013 May; 32(5):533-8. PubMed ID: 23453573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
    Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
    J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure.
    Flores-Blanco PJ; Manzano-Fernández S; Pérez-Calvo JI; Pastor-Pérez FJ; Ruiz-Ruiz FJ; Carrasco-Sánchez FJ; Morales-Rull JL; Pascual-Figal D; Galisteo-Almeda L; Januzzi JL
    Clin Cardiol; 2015 Feb; 38(2):106-13. PubMed ID: 25663560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction.
    Kubánek M; Goode KM; Lánská V; Clark AL; Cleland JG
    Eur J Heart Fail; 2009 Apr; 11(4):367-77. PubMed ID: 19179406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.